Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Trince logo — Precision Transfections

Trince

Precision Transfections

Founded 2014 Belgium Belgium 23 employees Total: $11.20M Biopharma, Biotechnology +1

General Information

Company Name Trince
Founded Year 2014
Location Belgium Belgium
Founders / Decision Makers
Team member
Employees 23
Industries Biopharma, Biotechnology, Pharmaceutical
Business Model B2B, D2C, Platform
Revenue Model Product Sales, Licensing, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Trince. To contact Trince, visit trincebio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Trince compare?

A PDF of Trince and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Trince soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Trince

Trince, founded in 2014, is a promising biotechnology startup headquartered in Belgium. This spin-off from Ghent University is advancing the biopharma landscape with their pioneering LumiPore transfection platform, which is covered by a portfolio of pending patents.

The core innovation lies in the fusion of laser technology with photothermal nanoparticles to transiently permeabilize the cellular plasma membrane. This enables the precise delivery of a diverse range of effector molecules, including hard-to-transfect cells such as immune cells crucial for cell therapies. It elevates the efficiency of cell products for therapeutics, ensuring gentleness and quality.

Trince's commitment to precision transfections positions them within the Biopharma, Biotechnology, and Pharmaceutical industries. The company most recently secured a substantial €5.20M early VC investment in December 2025, showcasing robust confidence from investors in their innovative capacity and growth trajectory.

Business keywords: cell-based science, therapeutics, molecule delivery, in vitro transfection, ex vivo transfection, LumiPore platform, photothermal nanoparticles, laser exposure, cell therapy, genetic material, high-throughput transfection, immune cells, cell permeabilization, hard-to-transfect cells

Services & Products

Photoporation
LumiPore Cell Transfection Platform
Research and Development Support
Cell Therapy Manufacturing

Target Customers

Biotech Researchers Clinical Researchers Pharmaceutical Companies Academic Institutions

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC €5.20M -
01 Dec 2025
Seed €2.00M 2
QBIC Novalis Biotech
QBIC, Novalis Biotech
01 Feb 2024
Spinout €4.00M 2
QBIC Novalis Biotech
QBIC, Novalis Biotech
01 Dec 2021

Trince Alternatives & Competitors

View All Alternatives
Trince vs
GenEdit
GenEdit United States

Delivering the potential of genetic medicines

Series A
47 employees
Biotechnology, Health and Wellness
Trince vs
T&L Biotechnology
T&L Biotechnology United States

Provide One-Stop Products and Services for CGT Research

Series A
12 employees
Biopharma, Biotechnology
Trince vs
Bruker Dynamic Biosensors
Bruker Dynamic Biosensors Germany

Bruker Dynamic Biosensors provides analytical systems for the characterization of biomolecules & mol...

Series A
54 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Trince

Precision Transfections
Trince was founded in 2014.
Trince is headquartered in Belgium.
Trince operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on cell-based science, therapeutics, molecule delivery and in vitro transfection. Its customers include Biotech Researchers, Clinical Researchers and Pharmaceutical Companies.
Trince has a B2B, D2C and Platform business model. Its revenue comes from Product Sales, Licensing and Service Fee.
Trince has approximately 23 employees.
Trince has completed 3 funding rounds, raising a total of $11.20M.
Trince offers: Photoporation, LumiPore Cell Transfection Platform, Research and Development Support, Cell Therapy Manufacturing.
Top alternatives and competitors to Trince include GenEdit, T&L Biotechnology, Bruker Dynamic Biosensors, MDVerse, Umoja Biopharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Trince and GenEdit are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Trince, https://bouncewatch.com/company/trince, updated 7 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes